Several recent studies established the antitumor potential of ADA in solid malignancies, including HCC, colon cancer, melanoma, ovarian cancer, and prostate cancer (Shi et al., 2015; Ghosalkar et al., 2018; Li et al., 2019; Wang et al., 2019; Nong et al., 2022). This evidence concerns the gene ADA and melanoma.